Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Bennett

Showing results (161-170 of 331) with videos related to

Pageof 34
Sort By:
Pharmacoeconomics|December 18, 2009
Adverse drug interactions: moving from perception to actionRyan Mayhew, June M McKoy, Thanh Ha Luu, et al.
Archives of Internal Medicine|September 15, 2010
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agentsCharles L Bennett, Stephen Y Lai, Michael Henke, et al.
Community Oncology|January 5, 2010
Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatmentJune M McKoy, Carlos R Bolden, Athena Samaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse OutcomeJohn Bian, Brian Chen, Dawn L Hershman, et al.
The Journal of Community and Supportive Oncology|February 27, 2016
Joint breast and colorectal cancer screenings in medically underserved womenTerry C Davis, Connie L Arnold, Michael S Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizationsCharles L Bennett, Mark R Somerfield, David G Pfister, et al.
Archives of Internal Medicine|March 26, 2008
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006Benjamin Djulbegovic, Ambuj Kumar, Heloisa P Soares, et al.
Journal of Women'S Health (2002)|February 19, 2015
Sustaining mammography screening among the medically underserved: a follow-up evaluationTerry C Davis, Connie L Arnold, Charles L Bennett, et al.
Medicina (Kaunas, Lithuania)|December 24, 2021
A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal DisordersDeanna N Cannizzaro, Lydia F Naughton, Maya Z Freeman, et al.
The Lancet. Oncology|February 19, 2017
Generic drugs in oncology - Authors' replyCharles L Bennett, Sumimasa Nagai, Y Tony Yang, et al.
Pageof 34

Showing results (161-170 of 331) with videos related to

Sort By:
Pageof 34
Pharmacoeconomics|December 18, 2009
Adverse drug interactions: moving from perception to actionRyan Mayhew, June M McKoy, Thanh Ha Luu, et al.
Archives of Internal Medicine|September 15, 2010
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agentsCharles L Bennett, Stephen Y Lai, Michael Henke, et al.
Community Oncology|January 5, 2010
Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatmentJune M McKoy, Carlos R Bolden, Athena Samaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse OutcomeJohn Bian, Brian Chen, Dawn L Hershman, et al.
The Journal of Community and Supportive Oncology|February 27, 2016
Joint breast and colorectal cancer screenings in medically underserved womenTerry C Davis, Connie L Arnold, Michael S Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizationsCharles L Bennett, Mark R Somerfield, David G Pfister, et al.
Archives of Internal Medicine|March 26, 2008
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006Benjamin Djulbegovic, Ambuj Kumar, Heloisa P Soares, et al.
Journal of Women'S Health (2002)|February 19, 2015
Sustaining mammography screening among the medically underserved: a follow-up evaluationTerry C Davis, Connie L Arnold, Charles L Bennett, et al.
Medicina (Kaunas, Lithuania)|December 24, 2021
A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal DisordersDeanna N Cannizzaro, Lydia F Naughton, Maya Z Freeman, et al.
The Lancet. Oncology|February 19, 2017
Generic drugs in oncology - Authors' replyCharles L Bennett, Sumimasa Nagai, Y Tony Yang, et al.
Pageof 34